Journal article
BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab
R Dobson, AK Ghosh, B Ky, T Marwick, M Stout, A Harkness, R Steeds, S Robinson, D Oxborough, D Adlam, S Stanway, B Rana, T Ingram, L Ring, S Rosen, C Plummer, C Manisty, M Harbinson, V Sharma, K Pearce Show all
Jacc Cardiooncology | ELSEVIER | Published : 2021
Abstract
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor receptor (HER) 2-positive targeted treatment (e.g., trastuzumab and pertuzumab) form a significant proportion of cardio-oncology..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by National Institutes of Health grant R01 HL 118018 (Dr. Ky). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.